

(12) United States Patent

Dhuppad et al.

(54) STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE

(71) Applicant: GLENMARK SPECIALTY S.A., La

Chaux-de-Fonds (CH)

(72) Inventors: **Ulhas R. Dhuppad**, Maharashtra (IN); Ashok Katkurwar, Maharashtra (IN);

Yashwant Gupta, Maharashtra (IN); Rajesh Ankam, Maharashtra (IN); Chandrakant Dhatrak, Maharashtra

(73) Assignee: GLENMARK SPECIALTY S.A., La

Chaux-de-Fonds (CH)

Subject to any disclaimer, the term of this (*) Notice:

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 15/703,828

(22)Filed: Sep. 13, 2017

(65)**Prior Publication Data**

> US 2018/0000844 A1 Jan. 4, 2018

Related U.S. Application Data

(63) Continuation of application No. 15/210,692, filed on Jul. 14, 2017, now Pat. No. 9,937,189, which is a continuation-in-part of application No. 15/183,534, filed on Jun. 15, 2016, now Pat. No. 9,750,754, which is a continuation of application No. 14/662,128, filed on Mar. 18, 2015, now Pat. No. 9,370,483, which is a continuation-in-part of application No. 14/483,837, filed on Sep. 11, 2014, now Pat. No. 9,078,923, which is a continuation-in-part of application No. PCT/IB2014/064251, filed on Sep. 4, 2014.

(30)Foreign Application Priority Data

Sep. 13, 2013 (IN) 2975/MUM/2013

(51) Int. Cl. A61K 31/58 (2006.01)A61K 9/00 (2006.01)A61K 9/10 (2006.01)A61K 31/335 (2006.01)A61K 47/36 (2006.01)A61K 47/38 (2006.01)

(52) U.S. Cl.

CPC A61K 31/58 (2013.01); A61K 9/0043 (2013.01); A61K 9/10 (2013.01); A61K 31/335 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01)

(58) Field of Classification Search

CPC A61K 2300/00; A61K 9/0043; A61K 31/573; A61K 31/335; A61K 31/58; A61K 31/355; A61K 31/5513; A61K (10) Patent No.: US 10,765,686 B2

(45) **Date of Patent:** *Sep. 8, 2020

> 31/575; A61K 9/10; A61K 31/00; A61K 31/56; A61K 31/57; A61K 31/7048; A61K 47/38; A61K 47/36; A61K 31/445; A61K 31/496; A61K 47/02; A61K 47/32; A61K 9/0073; A61K 9/145; A61K 9/146; A61K 31/55; A61K 47/186; A61K 47/26; A61P 11/02; A61P 37/08; A61P 29/00; A61P 11/00; A61P 27/14; A61P 11/06; A61P 17/00; A61P 27/02; A61P 31/04; A61P 31/10; A61P 31/12; A61P 43/00; A61P 5/44

See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

4,871,865	A	10/1989	Lever, Jr. et al.
4,923,892	A	5/1990	Lever, Jr. et al.
5,837,699	A	11/1998	Sequeira et al.
6,127,353	A	10/2000	Yuen et al.
6,841,146	B2	1/2005	Haslwanter et al.
7,977,376	B2	7/2011	Singh et al.
8,399,508	B2	3/2013	Singh et al.
9,078,923	B2	7/2015	Dhuppad et al.
9,370,483	B2	6/2016	Dhuppad et al.
9,750,754	B2*	9/2017	Dhuppad A61K 31/58
			424/401
2004/0097474	A1*	5/2004	Cagle A61K 9/0043
			514/171
2006/0110328	A1*	5/2006	Cagle A61K 31/00
			424/45
2007/0099883	A1	5/2007	Calis et al.
(Continued)			
(Continued)			

FOREIGN PATENT DOCUMENTS

WO WO-1995020393 A1 8/1995 WO-2001026658 WO 4/2001 (Continued)

OTHER PUBLICATIONS

Avicel® RC-591, Product Specification Bulletin, Feb. 2009. (Continued)

Primary Examiner — Audrea B Coniglio (74) Attorney, Agent, or Firm — Blank Rome LLP

(57)**ABSTRACT**

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

14 Claims, No Drawings